Kathryn E Falberg is Director of Arcus Biosciences, Inc.. Currently has a direct ownership of 55,300 shares of RCUS, which is worth approximately $857,150. The most recent transaction as insider was on Jun 06, 2024, when has been sold 8,400 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 55.3K
0% 3M change
37.91% 12M change
Total Value Held $857,150

KATHRYN E FALBERG Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 06 2024
BUY
Grant, award, or other acquisition
-
8,400 Added 13.19%
55,300 Common Stock
Jun 15 2023
SELL
Bona fide gift
-
50,504 Reduced 55.74%
40,100 Common Stock
Jun 15 2023
BUY
Grant, award, or other acquisition
-
6,800 Added 12.66%
46,900 Common Stock
Jun 14 2022
BUY
Grant, award, or other acquisition
-
4,100 Added 4.33%
90,604 Common Stock
Jun 03 2021
BUY
Grant, award, or other acquisition
-
3,000 Added 3.35%
86,504 Common Stock

Also insider at

TTD
Trade Desk, Inc. Technology
NUVB
Nuvation Bio Inc. Healthcare
TCDA
Tricida, Inc. Healthcare
URGN
UroGen Pharma Ltd. Healthcare
KEF

Kathryn E Falberg

Director
Ventura, CA

Track Institutional and Insider Activities on RCUS

Follow Arcus Biosciences, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RCUS shares.

Notify only if

Insider Trading

Get notified when an Arcus Biosciences, Inc. insider buys or sells RCUS shares.

Notify only if

News

Receive news related to Arcus Biosciences, Inc.

Track Activities on RCUS